drugset / Trial / NCT05574504
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
NaSingle-groupOpen-labelTreatment
Summary
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based chemotherapy
Timeline
- Start
- 2023-05-08
- Primary completion
- 2026-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Lurbinectedin | Other / unclassified | 3.2 mg/m2 | Intravenous |